-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Primary liver cancer (PLC) is the fourth leading cause of cancer-related death worldwide
The number of long-term cancer survivors continues to rise as cancer treatments evolve and early diagnosis rates increase
This study used data from the Surveillance, Epidemiology and End Results (SEER) database to analyze the survival of PLC patients with and without thyroid cancer to determine whether a history of thyroid cancer affects the survival of PLC patients
Eligible PLC patients were selected from data from the Surveillance, Epidemiology and End Results (SEER) database for the period 2004-2016
A total of 142 PLC patients with a history of thyroid cancer and 1420 PLC patients without previous thyroid cancer were included in the study
The median survival time of PLC patients was 11.
A subgroup analysis stratified by sex showed a similar relationship between women and PLC: women with previous thyroid cancer had a lower risk of death from PLC (HR = 0.
Figure 3a depicts the cumulative incidence of PLC-specific death between female PLC patients with and without previous thyroid cancer
Overall, prior thyroid cancer reduces the risk of PLC-specific death in PLC patients, especially women
Original source:
Liu, H.